Three Years On | 合法醫療器材資訊網

2019年4月30日—TheAbsorbBVSstoryneverdeliveredthehoped-forhappyending.ThebioresorbablescaffoldfirstreceivedCEMarkapprovalinEuropein ...

Three years after PCI, there is no significant difference in myocardial perfusion among patients who received the now-discontinued Absorb bioresorbable vascular scaffold (BVS; Abbott Vascular) compared with those who received a conventional drug-eluting stent, according to the results of the VANISH study.

The Absorb device should have been completely degraded at 3 years, which would allow the artery to heal and assume its normal geometry, but the present study challenges the hypothesized beneficial effects of scaffold resorption given the lack of improvement in myocardial blood flow, say investigators.

“The results are disappointing in the sense that the whole hypothesis—based on the idea that degradation of the scaffold would lead to a healthier vessel, which wou...